Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of Adjuvant Docetaxel-Carboplatin Treatment for Resected Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Non-small cell lung cancer stage IB - IIIA, complete resection with mediastinal lymph node dissection~* ECOG status 0-1~* \>14 and \<56 days since resection~Exclusion Criteria:~* Prior chemotherapy and/or radiation therapy for lung cancer~* Peripheral neuropathy \> grade 1~* Concurrent other malignancies, other than basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix~* Medical condition that will not permit treatment or follow up according to the protocol~* Prior treatment with docetaxel or carboplatin~* Hypersensitivity to polysorbate 80, platinum-containing compounds or mannitol~* Treatment with other investigational anti-cancer drugs within 30 days of registration~* Pregnant or nursing women~* HIV-positive patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Docetaxel: 75 mg/m2 over 1 hour every 3 weeks for 3 doses Carboplatin Area Under the Curve 5.5 over 0.5 to 1 hour every 3 weeks for 3 doses

Based on this trial design, predict the completion outcome and termination type (if applicable).